Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma

Access the press release on Exelixis’ website 

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019